- Home
- LGCL vs OSTX Comparison
LGCL vs OSTX Comparison
Compare LGCL & OSTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGCL
- OSTX
- Stock Information
- Founded
- LGCL 2009
- OSTX 2018
- Country
- LGCL China
- OSTX United States
- Employees
- LGCL N/A
- OSTX N/A
- Industry
- LGCL
- OSTX
- Sector
- LGCL
- OSTX
- Exchange
- LGCL NYSE
- OSTX NYSE
- Market Cap
- LGCL 47.7M
- OSTX 43.0M
- IPO Year
- LGCL 2024
- OSTX 2024
- Fundamental
- Price
- LGCL $1.07
- OSTX $1.81
- Analyst Decision
- LGCL
- OSTX Strong Buy
- Analyst Count
- LGCL 0
- OSTX 3
- Target Price
- LGCL N/A
- OSTX $18.00
- AVG Volume (30 Days)
- LGCL 277.5K
- OSTX 301.8K
- Earning Date
- LGCL 01-01-0001
- OSTX 08-14-2025
- Dividend Yield
- LGCL N/A
- OSTX N/A
- EPS Growth
- LGCL N/A
- OSTX N/A
- EPS
- LGCL 0.07
- OSTX N/A
- Revenue
- LGCL $145,690,427.00
- OSTX N/A
- Revenue This Year
- LGCL N/A
- OSTX N/A
- Revenue Next Year
- LGCL N/A
- OSTX N/A
- P/E Ratio
- LGCL $9.92
- OSTX N/A
- Revenue Growth
- LGCL N/A
- OSTX N/A
- 52 Week Low
- LGCL $0.28
- OSTX $1.12
- 52 Week High
- LGCL $3.31
- OSTX $7.00
- Technical
- Relative Strength Index (RSI)
- LGCL N/A
- OSTX N/A
- Support Level
- LGCL N/A
- OSTX N/A
- Resistance Level
- LGCL N/A
- OSTX N/A
- Average True Range (ATR)
- LGCL 0.00
- OSTX 0.00
- MACD
- LGCL 0.00
- OSTX 0.00
- Stochastic Oscillator
- LGCL 0.00
- OSTX 0.00
About LGCL LUCAS GC LIMITED
Lucas GC Ltd is a technology-driven online agent-centric human capital management service provider targeting professionals based on PaaS in China. Its business segments consist of recruitment services, outsourcing services, and other services, which include information technology services and training services.
About OSTX OS THERAPIES INCORPORATED
OS Therapies Inc is a clinical stage biopharmaceutical company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. The companys mission is to address the need for new treatments in cancers of the bone in children and young adults.